At a meeting on “translational research,” a senior member of a contract-research organization – a company that provides outsourced research services to the pharmaceutical and biotechnology industries – articulated the problem. “What really frustrates us,” he commented, “is to be commissioned by a pharmaceutical company to design an early-phase trial when we know already that it is going up a blind alley.
在一次名为“翻译研究”的会议上，一家为制药和生物技术产业提供外包研究的合同研究机构高层人员明确指出了这一问题。他说，“真正让我们灰心丧气的是接到制药公司设计早期试验的委托，而我们已经知道这条路根本走不通。我们之所以清楚这一点是因为在接受另一家公司委托时已经走进过死胡同；但由于商业原因上述结果并未公之于众。”